Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Phase III Data Showed Novartis Investigational Bronchodilator QAB149 Significantly Improved Lung Function In COPD Patients
The Novartis investigational bronchodilator QAB149 (indacaterol) met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease (COPD) patients. In secondary endpoints of these studies, QAB149 demonstrated clinically relevant lung function improvements within five minutes of the first dose, lasting for 24 hours in COPD patients.
generic viagra online
Editorial, Opinion Piece Discuss Issues Related To Routine HIV Testing
A recent directive to streamline the HIV testing consent process in Massachusetts as well as consent forms "no longer hav[ing] to accompany test specimens to the lab," are bringing "the state closer to a CDC recommendation that clinicians provide HIV screening on an opt-out basis," according to a Boston Globe editorial. "The opt-out provision is at the heart" of legislation sponsored by state Sen. Patricia Jehlen (D) that would end the state"s requirement of written consent for HIV testing "and instead have healthcare providers inform patients verbally that the test is planned but that they can decline it," the editorial states, adding, "The Jehlen bill would help destigmatize HIV testing itself" (7/6).
News of the day
Media Coverage Generates 47% Increase In Melanoma Diagnoses
Media coverage of skin cancer advice and sun awareness campaigns may have generated a 47 percent increase in diagnoses of melanoma in just one year, according to research due to be released at the British Association of Dermatologists" Annual Conference next week.
Diagnostics

UK To Play Lead Role In European Fight Against Dementia

The UK will play a leading role in coordinated European action to tackle dementia from. A new initiative launched by the European Commission has adopted proposals to tackle Alzheimer"s disease, dementias and other neurodegenerative conditions. The UK is one of ten countries that will lead research aimed at tackling shared health and social care problems. According to the Commission there are over seven million people with Alzheimer"s disease and related disorders in Europe and it is predicted that this number will double in the next 20 years. Today"s actions mark new steps both in the Commission"s "Europe for Patients campaign" and the new approach of Joint Programming in research. Dr Susanne Sorensen, Head of Research, Alzheimer"s Society says, "Building on successful high impact dementia research, the UK will play a critical role in this initiative, leading the fight to defeat dementia. By uniting to find a cause, cure and fund care, we can galvanise our efforts and offer hope to millions of people. "But while Europe strives forward, the UK government still lags behind the US, Germany and France in providing dementia research funding and there is still no specifically targeted dementia research funding. Yesterday the government promised to develop a strategy for investment in dementia research. It must make good on its promises or we will all pay the price." In an open letter to the government yesterday, 31 leading dementia researchers united to call for a national plan for dementia research and a tripling of current investment. The letter coincides with a unique ministerial research summit on dementia which stated the importance of increasing research funding spent on dementia. Experts agree the UK must follow the French model for dementia research which provides a focussed structure to support the full breadth of cause, cure and care research. Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009